van Rooijen G J, Boer P, Dorhout Mees E J, Geyskes G G
Clin Pharmacol Ther. 1979 Oct;26(4):420-7. doi: 10.1002/cpt1979264420.
The antihypertensive effects of atenolol and propranolol were compared in a double-blind crossover study of 19 patients with essential hypertension (World Health Organization, I and II) who were receiving long-term diuretic treatment (chlorthalidone, 50 mg daily) during the study. After a 3-wk placebo period, a beta-adrenergic antagonist was administered once daily (atenolol, 50 mg daily, or propranolol, 80 mg daily) for a week. If the MAP was more than 108 mm Hg at the end of the week, dosage of the beta-blocker was doubled the following week; when necessary, doubling was repeated to a maximum dose of 640 mg propranolol and 400 mg atenolol daily. Fifty milligrams atenolol had a greater effect than 80 mg propranolol and was as effective as 160 mg propranolol. The dose-response curve flattened off after 160 mg propranolol and 50 mg atenolol daily. The two highest doses of atenolol lowered MAP more than the highest doses of propranolo. Heart rate slowing was the same for both drugs and did not correlate with the fall in blood pressure. PRA was suppressed by all doses of propranolol, whereas atenolol suppressed PRA only at the 2 highest doses, (200 and 400 mg daily). With the lower propranolol doses, the percent MAP change correlated weakly with the percent PRA change (80 mg--r = 0.41, p less than 0.1; 160 mg--r = 0.64, p less than 0.05). Side effects were minimal, and were noted only with 640 mg propranolol; with this exception, the percentage of patients with no complaints rose when placebo was replaced by beta-blockers.
在一项双盲交叉研究中,对19例原发性高血压(世界卫生组织I级和II级)患者的阿替洛尔和普萘洛尔的降压效果进行了比较,这些患者在研究期间接受长期利尿剂治疗(氯噻酮,每日50mg)。经过3周的安慰剂期后,每天服用一次β-肾上腺素能拮抗剂(阿替洛尔,每日50mg,或普萘洛尔,每日80mg),持续一周。如果在该周结束时平均动脉压(MAP)超过108mmHg,则在接下来的一周将β受体阻滞剂剂量加倍;必要时,重复加倍至普萘洛尔最大剂量每日640mg和阿替洛尔每日400mg。50mg阿替洛尔比80mg普萘洛尔有更大的效果,且与160mg普萘洛尔效果相当。每日160mg普萘洛尔和50mg阿替洛尔后剂量反应曲线趋于平缓。阿替洛尔的两个最高剂量降低MAP的幅度大于普萘洛尔的最高剂量。两种药物使心率减慢的程度相同,且与血压下降无关。所有剂量的普萘洛尔均抑制肾素活性(PRA),而阿替洛尔仅在两个最高剂量(每日200mg和400mg)时抑制PRA。使用较低剂量普萘洛尔时,MAP变化百分比与PRA变化百分比的相关性较弱(80mg - r = 0.41,p < 0.1;160mg - r = 0.64,p < 0.05)。副作用极小,仅在640mg普萘洛尔时出现;除此之外,当用β受体阻滞剂替代安慰剂时,无不适主诉的患者百分比增加。